Optimizing antibody therapies against antibiotic-resistant Klebsiella in High-Risk patients
Official title: Optimization of therapeutic mAbs to carbapenem resistant Klebsiella clone ST258
Funded at Northport VA Medical Center · NIH-11264856 · Data updated 2026-11-12
A patient-focused look at improving monoclonal antibodies that target hard-to-treat Klebsiella infections in people who are seriously ill or recovering in hospital settings.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northport VA Medical Center NIH-funded |
| Lab location | 1 site (Northport, United States) |
| Project start | January 1, 2019 |
| Project end | September 30, 2028 |
| Funding year | 2027 |
| NIH project number | 5I01BX003741-07 |
| Project ID | NIH-11264856 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with CR-Kp infections or those at high risk in hospital settings, including individuals with complicated wounds or invasive infections.
✕Less likely to help
People without CR-Kp infection or exposure may not benefit from this research.
What this research studies
This project aims to refine monoclonal antibodies that target the capsule of carbapenem-resistant Klebsiella pneumoniae (CR-Kp), focusing on making them effective against diverse capsule types and in patients with multiple health issues. Researchers plan to build on existing antibodies that protect against CR-Kp and adapt them to cover additional strains found in healthcare settings, including emerging clones. The work involves laboratory testing on relevant human-derived samples and models to ensure safety and potential effectiveness in patients who develop pneumonia, sepsis, or urinary infections from CR-Kp. If successful, this could pave the way for antibody-based treatments that complement antibiotics for people at high risk of CR-Kp-related complications.
Why it matters
Potential benefit: If successful, patients with CR-Kp infections could have a new antibody-based option to help prevent or treat severe infections.
How similar studies have gone: Previous work shows monoclonal antibodies against the capsule can be protective, and this grant seeks to broaden protection to more capsule types.
Where this research is happening
-
Northport VA Medical Center
Northport, United States Active
Researchers
- Principal investigator: Fries, Bettina — Northport VA Medical Center
- Study coordinator: Fries, Bettina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.